Prehospital tirofiban increases the rate of disrupted myocardial infarction in patients with ST-segment elevation myocardial infarction: insights from the On-TIME 2 trial.
Sem A O F RikkenEnrico FabrisTobias RosenqvistEvangelos GiannitsisJurriën M Ten BergChristian W HammArnoud W J van 't HofPublished in: European heart journal. Acute cardiovascular care (2024)
Among STEMI patients undergoing primary PCI, the use of prehospital tirofiban was independently associated with a higher rate of disrupted MI. These results, highlighting a potential benefit, underscore the need for future research focusing on innovative pre-treatment approaches that may increase the rate of disrupted MI.
Keyphrases
- st segment elevation myocardial infarction
- percutaneous coronary intervention
- patients undergoing
- st elevation myocardial infarction
- cardiac arrest
- acute coronary syndrome
- acute myocardial infarction
- resting state
- coronary artery disease
- antiplatelet therapy
- clinical trial
- trauma patients
- heart failure
- coronary artery bypass grafting
- current status
- study protocol
- randomized controlled trial
- atrial fibrillation
- emergency medical
- combination therapy
- climate change
- coronary artery bypass